Promising Practices Observed in High-Throughput Covid-19 Vaccination Sites in the United States, February–May 2021

Bibliographic Data

ID11034348
AuthorsCaitlin E McColloch (All authors are with the COVID-19 Response’s Vaccine Task Force, Centers for Disease Control and Prevention (CDC), Atlanta, GA.), Caitlin McColloch (Centers for Disease Control and Prevention), Marsha E Samson (0000-0002-8634-2911, All authors are with the COVID-19 Response’s Vaccine Task Force, Centers for Disease Control and Prevention (CDC), Atlanta, GA.), KaeAnne Parris (0000-0001-6823-8240, All authors are with the COVID-19 Response’s Vaccine Task Force, Centers for Disease Control and Prevention (CDC), Atlanta, GA.), Amy Stewart (0000-0002-5324-2025, All authors are with the COVID-19 Response’s Vaccine Task Force, Centers for Disease Control and Prevention (CDC), Atlanta, GA.), Amy Bellinghausen Stewart (Centers for Disease Control and Prevention), Judith A Robinson (All authors are with the COVID-19 Response’s Vaccine Task Force, Centers for Disease Control and Prevention (CDC), Atlanta, GA.), Barbara M Cooper (0000-0002-5136-8783, Centers for Disease Control and Prevention), Barbara Cooper (All authors are with the COVID-19 Response’s Vaccine Task Force, Centers for Disease Control and Prevention (CDC), Atlanta, GA.), Eboni Galloway (0000-0002-2025-3473, All authors are with the COVID-19 Response’s Vaccine Task Force, Centers for Disease Control and Prevention (CDC), Atlanta, GA.), Robert Garcia (0000-0002-3780-9319, All authors are with the COVID-19 Response’s Vaccine Task Force, Centers for Disease Control and Prevention (CDC), Atlanta, GA.), Zunera Gilani (All authors are with the COVID-19 Response’s Vaccine Task Force, Centers for Disease Control and Prevention (CDC), Atlanta, GA.), Bina Jayapaul-Philip (All authors are with the COVID-19 Response’s Vaccine Task Force, Centers for Disease Control and Prevention (CDC), Atlanta, GA.), Patrick Lucas (0000-0003-0292-7830, Centers for Disease Control and Prevention), Paul Lucas (All authors are with the COVID-19 Response’s Vaccine Task Force, Centers for Disease Control and Prevention (CDC), Atlanta, GA.), Kimberly H Nguyen (0000-0002-3558-6983, All authors are with the COVID-19 Response’s Vaccine Task Force, Centers for Disease Control and Prevention (CDC), Atlanta, GA.), Rebecca S Noe (All authors are with the COVID-19 Response’s Vaccine Task Force, Centers for Disease Control and Prevention (CDC), Atlanta, GA.), Aimée-Rika T Trudeau (All authors are with the COVID-19 Response’s Vaccine Task Force, Centers for Disease Control and Prevention (CDC), Atlanta, GA.), Erin D Kennedy (0000-0001-7383-0900, All authors are with the COVID-19 Response’s Vaccine Task Force, Centers for Disease Control and Prevention (CDC), Atlanta, GA.)
Year2023
Volume113
Issue8
Pages909-918
Publication date2023-08-01
Peer ReviewedYes
Open AccessNo
TypeARTICLE
VenueAmerican Journal of Public Health (JOURNAL)
Journal identifiersISSN: 0090-0036 • E-ISSN: 1541-0048
PublisherAmerican Public Health Association (PUBLISHER • US)
DOI10.2105/ajph.2023.307331
PMID37406267
OpenAlexW4383302620
LanguageEN
References cited19

Objectives. To identify promising practices for implementing COVID-19 vaccination sites. Methods. The Centers for Disease Control and Prevention (CDC) and Federal Emergency Management Agency (FEMA) assessed high-throughput COVID-19 vaccination sites across the United States, including Puerto Rico, after COVID-19 vaccinations began. Site assessors conducted site observations and interviews with site staff. Qualitative data were compiled and thematically analyzed. Results. CDC and FEMA conducted 134 assessments of high-throughput vaccination sites in 25 states and Puerto Rico from February 12 to May 28, 2021. Promising practices were identified across facility, clinical, and cross-cutting operational areas and related to 6 main themes: addressing health equity, leveraging partnerships, optimizing site design and flow, communicating through visual cues, using quick response codes, and prioritizing risk management and quality control. Conclusions. These practices might help planning and implementation of future vaccination operations for COVID-19, influenza, and other vaccine-preventable diseases. Public Health Implications. These practices can be considered by vaccination planners and providers to strengthen their vaccination site plans and implementation of future high-throughput vaccination sites. (Am J Public Health. 2023;113(8):909–918. https://doi.org/10.2105/AJPH.2023.307331 )

2019-20 coronavirus outbreak · Betacoronavirus · Coronavirus disease 2019 (COVID-19) · Coronavirus Infections · Environmental health · Family medicine · Outbreak · Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) · Sociology · Telecommunications · Throughput · Vaccination · Computer Science · COVID-19 epidemiological studies · Demography · Internal Medicine · Medicine · SARS-CoV-2 and COVID-19 Research · Vaccine Coverage and Hesitancy · Virology

Tools

Open DOIOpen Access